Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Jean-Philippe

Showing results (71-80 of 83) with videos related to

Pageof 9
Sort By:
The New England Journal of Medicine|October 3, 2019
Isoniazid Preventive Therapy in HIV-Infected Pregnant and Postpartum WomenAmita Gupta, Grace Montepiedra, Lisa Aaron, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 13, 2026
Hypertension in a randomized trial of dolutegravir- versus efavirenz-based antiretroviral therapy in pregnant and postpartum women with HIVRisa Hoffman, Sean Brummel, Mauricio Pinilla, et al.
Cell Reports|July 20, 2022
Immune correlates of HIV-1 reservoir cell decline in early-treated infantsCiputra Adijaya Hartana, Pilar Garcia-Broncano, Yelizaveta Rassadkina, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 15, 2015
Toward Earlier Inclusion of Pregnant and Postpartum Women in Tuberculosis Drug Trials: Consensus Statements From an International Expert PanelAmita Gupta, Jyoti S Mathad, Susan M Abdel-Rahman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 5, 2024
Weight Changes and Adverse Pregnancy Outcomes With Dolutegravir- and Tenofovir Alafenamide Fumarate-Containing Antiretroviral Treatment Regimens During Pregnancy and PostpartumRisa M Hoffman, Sean Brummel, Lauren Ziemba, et al.
The Lancet. HIV|May 11, 2023
Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trialLameck Chinula, Lauren Ziemba, Sean Brummel, et al.
The Journal of Infectious Diseases|June 5, 2024
Pharmacokinetics and Safety of Remdesivir in Pregnant and Nonpregnant Women With COVID-19: Results From IMPAACT 2032Kristina M Brooks, Kristin Baltrusaitis, Diana F Clarke, et al.
The Lancet. Infectious Diseases|May 11, 2015
Towards early inclusion of children in tuberculosis drugs trials: a consensus statementSharon Nachman, Amina Ahmed, Farhana Amanullah, et al.
Science Translational Medicine|July 5, 2023
Broadly neutralizing antibody treatment maintained HIV suppression in children with favorable reservoir characteristics in BotswanaRoger L Shapiro, Gbolahan Ajibola, Kenneth Maswabi, et al.
The Journal of Infectious Diseases|March 27, 2012
Evaluation of tuberculosis diagnostics in children: 1. Proposed clinical case definitions for classification of intrathoracic tuberculosis disease. Consensus from an expert panelStephen M Graham, Tahmeed Ahmed, Farhana Amanullah, et al.
Pageof 9

Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
The New England Journal of Medicine|October 3, 2019
Isoniazid Preventive Therapy in HIV-Infected Pregnant and Postpartum WomenAmita Gupta, Grace Montepiedra, Lisa Aaron, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 13, 2026
Hypertension in a randomized trial of dolutegravir- versus efavirenz-based antiretroviral therapy in pregnant and postpartum women with HIVRisa Hoffman, Sean Brummel, Mauricio Pinilla, et al.
Cell Reports|July 20, 2022
Immune correlates of HIV-1 reservoir cell decline in early-treated infantsCiputra Adijaya Hartana, Pilar Garcia-Broncano, Yelizaveta Rassadkina, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 15, 2015
Toward Earlier Inclusion of Pregnant and Postpartum Women in Tuberculosis Drug Trials: Consensus Statements From an International Expert PanelAmita Gupta, Jyoti S Mathad, Susan M Abdel-Rahman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 5, 2024
Weight Changes and Adverse Pregnancy Outcomes With Dolutegravir- and Tenofovir Alafenamide Fumarate-Containing Antiretroviral Treatment Regimens During Pregnancy and PostpartumRisa M Hoffman, Sean Brummel, Lauren Ziemba, et al.
The Lancet. HIV|May 11, 2023
Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trialLameck Chinula, Lauren Ziemba, Sean Brummel, et al.
The Journal of Infectious Diseases|June 5, 2024
Pharmacokinetics and Safety of Remdesivir in Pregnant and Nonpregnant Women With COVID-19: Results From IMPAACT 2032Kristina M Brooks, Kristin Baltrusaitis, Diana F Clarke, et al.
The Lancet. Infectious Diseases|May 11, 2015
Towards early inclusion of children in tuberculosis drugs trials: a consensus statementSharon Nachman, Amina Ahmed, Farhana Amanullah, et al.
Science Translational Medicine|July 5, 2023
Broadly neutralizing antibody treatment maintained HIV suppression in children with favorable reservoir characteristics in BotswanaRoger L Shapiro, Gbolahan Ajibola, Kenneth Maswabi, et al.
The Journal of Infectious Diseases|March 27, 2012
Evaluation of tuberculosis diagnostics in children: 1. Proposed clinical case definitions for classification of intrathoracic tuberculosis disease. Consensus from an expert panelStephen M Graham, Tahmeed Ahmed, Farhana Amanullah, et al.
Pageof 9